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The spectrum effect in tests for risk prediction, screening, 
and diagnosis
Juliet A Usher-Smith,1 Stephen J Sharp,2 Simon J Griffin1,2 
The spectrum effect describes the 
variation between settings in 
performance of tests used to predict, 
screen for, and diagnose disease. In 
particular, the predictive use of a test 
may be different when it is applied in a 
general population rather than in the 
study sample in which it was first 
developed. This article discusses the 
impact of the spectrum effect on 
measures of test performance, and its 
implications for the development, 
evaluation, application, and 
implementation of such tests.
Much of clinical practice relies on using tests that 
measure one or more characteristics of an individual 
to determine whether that individual is at risk of 
developing a condition of interest, or does or does not 
have a particular disease. These tests include risk pre-
diction scores, screening tests, and diagnostic inves-
tigations. When evaluating the clinical performance 
of such tests, the most commonly used measures are 
the sensitivity, specificity, predictive value, likelihood 
ratio, and area under the receiver operating charac-
teristic curve (box 1). The likelihood ratio is multi-
plied by the pre-test odds of the condition to obtain 
the post-test odds, which can be converted to a post-
test probability (known as the positive predictive 
value). The positive predictive value is well known to 
vary with the prevalence of the condition. However, 
while the variation in likelihood ratio, sensitivity, and 
specificity due to the phenomenon known as the 
“spectrum effect” or “spectrum bias” has been well 
described,1-5 it is frequently overlooked by the wider 
medical and policy-making community when inter-
preting data on test performance.
In this article, we aim to highlight the importance of 
this effect to all those developing, evaluating, or 
implementing tests for prediction, screening, or diag-
nosis. We begin by discussing the spectrum effect in 
general with examples taken from the literature, and 
then use simulations to illustrate variation in the like-
lihood ratio, sensitivity, and specificity with preva-
lence and population distribution of the condition. 
Finally, we discuss the importance of considering the 
spectrum effect in the development, evaluation, and 
choice of tests.
What is the spectrum effect and why does it arise?
When Ransohoff and Feinstein first described the spec-
trum effect in 1978,5  they observed that the performance 
of a test in practice might be misrepresented by clinical 
studies that include too narrow a range of individuals 
with or without the disease of interest. Although they 
did not use the term “spectrum bias” explicitly, their 
discussion of a patient spectrum in a paper examining 
biases affecting diagnostic test research led to the use of 
the term to describe subgroup variation. This term 
“spectrum bias” is still used in the literature. We and 
others,6 however, prefer the term “spectrum effect,” 
because it better reflects the inherent nature of varia-
tion in test performance among population subgroups.
The implication of the spectrum effect is that the 
most commonly used measures of the performance of 
tests (sensitivity, specificity, and likelihood ratios) vary 
with the prevalence and distribution of disease in a 
population or sample. Only in situations with a truly 
dichotomous disease status or perfect test and an equal 
probability of diagnostic misclassification in individu-
als with and without the disease are these measures 
independent. These conditions are rarely met. Many 
situations have a continuum of (measurable or unmea-
surable) traits on which the classification of disease 
status is based, varying from clear absence to clear 
presence of the disease.7
Further, all tests are subject to error, including:
•	 Simple measurement error (eg, measurement of 
plasma glucose in the screening for type 2 diabetes, 
or measurement of D-dimer to guide further investi-
gations for suspected deep vein thrombosis or pul-
monary embolus)
•	 Subjective error when categorisations are based on 
patient recall, clinical symptoms, examination find-
ings, radiological images, or histological specimens 
that healthcare professionals could interpret differ-
ently (eg, colonoscopic identification of advanced 
adenoma or mammography for breast cancer)
•	 The influence of unmeasured covariates on test 
results. 
Summary pointS 
The spectrum effect describes the variation in performance of tests for prediction, 
screening, and diagnosis of disease among different population subgroups
A test developed in a population with a higher prevalence of disease (or at higher 
risk) will typically have a lower sensitivity and higher specificity when applied in a 
population with lower disease prevalence (or at lower risk)
Care should be taken when comparing the performance of tests developed and 
evaluated in different populations and using different methods
Ideally new tests should be developed and evaluated using data from the 
population(s) in which they are intended to be used
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This last source of error arises because few markers are 
specific to one disease, and so false positives are gener-
ated by conditions very close to but different from the 
target condition. For example, B type natriuretic pep-
tide can contribute to the diagnosis of heart failure, but 
might also be raised in several other conditions such as 
renal failure and pulmonary hypertension. 
The consequence of this combination of error in the 
test result and the continuum of true disease status is 
that the probability of misclassification of disease sta-
tus varies between individuals with individuals with 
true values of the underlying characteristics close to the 
cut-off point for diagnosis more likely to be misclassi-
fied than others.
How does the spectrum effect influence tests?
The effect of these errors on overall test performance 
depends on the proportion of individuals misclassified, 
which in turn depends on the number of individuals 
close to the cut-off point of the test. Therefore, the per-
formance of tests is influenced by both the prevalence 
of the condition or disease in the sample in which it is 
assessed and the characteristics of the sample. Using an 
approach similar to that demonstrated by Brenner and 
Gefeller,8 these effects can be illustrated by a simulated 
situation in which there is a continuous variable X with 
a value for each individual, and true disease status is 
defined by the value of X being above or below a partic-
ular threshold value (supplementary appendix).
X could represent an underlying trait—for example, 
true fasting glucose, for which the disease is diabetes 
and the threshold value for X is 7.0 mmol/L, or true sys-
tolic blood pressure, for which the disease is 
 hypertension and the threshold value is 150 mm Hg. 
However, X could also represent true underlying risk of 
a disease—for example, true underlying 10 year risk of 
cardiovascular disease can be classified as “high risk” 
or “low risk” on the basis of a threshold value for X. This 
particular threshold is currently 10% in England and 
Wales, as recommended by the National Institute for 
Health and Care Excellence to decide whether to offer 
statins.9
In all these examples, the true value of X for an indi-
vidual is unknown, but it is possible to obtain an esti-
mate (Z) of X, either by measurement of the trait of 
interest (fasting plasma glucose, systolic blood pres-
sure), or by calculation from a risk prediction model (10 
year cardiovascular risk). Z is unlikely to be exactly 
equal to X for all individuals, because of measurement 
error if X represents a measurable trait, or prediction 
error if X represents an underlying risk.
By varying the assumptions about the distribution of 
X, it is possible to explore the variation in the perfor-
mance of a test based on Z in populations with different 
underlying prevalence of disease or distributions 
of risk.
Scenario 1
The prevalence of disease in the population can be var-
ied by changing the mean of X while keeping the 
threshold value constant (fig 1 ). As prevalence 
decreases, the positive likelihood ratio (LR+), negative 
likelihood ratio (LR−), and specificity increase, while 
sensitivity decreases, with 10-fold changes in likelihood 
ratios and variation of 30% in sensitivity and specificity 
(fig 1A and 1B ). Change in prevalence is equivalent to 
performing a test in different health settings. A diagnos-
tic procedure developed in secondary care among 
patients suspected of having a particular disease will 
typically have lower sensitivity and higher specificity 
when applied as a screening tool in primary care where 
disease prevalence is lower. The same effect is seen 
when applying the test in subgroups known to be at 
higher risk (the referral filter3). For example, if a new 
test for diabetes is evaluated in routine clinical practice 
in primary care, it is likely that general practitioners 
would initially test people with symptoms or risk fac-
tors. If the test had been designed to be used in such a 
high risk group then that approach would be appropri-
ate, but if the test had been designed for population 
based screening of asymptomatic individuals, the spec-
ificity in that high risk population will be lower—and 
the sensitivity higher—than estimated in the original 
development population.
Scenario 2
The prevalence of disease within the population can also 
be changed by altering the distribution of X. We did this 
by simulating a bimodal distribution for X  illustrating 
different potential situations from one in which only a 
small proportion of the overall population has the dis-
ease, to one in which nearly half the population has the 
disease (fig 2 ). When X has a distribution as shown in 
figure 2C , a greater proportion of people with the disease 
will have a value of X close to the threshold (and hence 
be at risk of test misclassification) than the correspond-
ing proportion in a distribution as shown in figure 2D . 
In other words, as the proportion of the overall popula-
tion with the disease increases, the risk of test misclassi-
fication among those with the disease decreases and—with 
this particular underlying distribution of X—the result is 
Box 1: Commonly used measures for evaluating the clinical performance of 
diagnostic and screening tests 
•	Sensitivity=the probability that an individual with the disease has a positive test 
result
•	Specificity=the probability that an individual without the disease has a negative 
test result
•	Positive predictive value=the probability that an individual with a positive test 
result has the disease
•	Negative predictive value=the probability that an individual with a negative test 
result does not have the disease
•	Positive likelihood ratio=the probability that an individual with the disease has a 
positive test result, divided by the probability that an individual without the disease 
has a positive test result (that is, sensitivity/(1−specificity))
•	Negative likelihood ratio=the probability that an individual with the disease has a 
negative test result, divided by the probability that an individual without the 
disease has a negative test result (that is, (1−sensitivity)/specificity)
•	Area under the receiver operating characteristic curve (AUROC)=the probability that 
a classifier will correctly rank a randomly chosen person with the disease higher 
than a randomly chosen person without the disease (that is, the area under a plot of 
sensitivity against (1−specificity))
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an increase in sensitivity and decrease in the negative 
likelihood ratio (fig 2A and 2B ). The wide dispersion of 
the values of X in this bimodal distribution also means 
that in figure 2C and 2D , there are fewer individuals with 
values close to the threshold than in scenario 1 (fig 1C and 
1D ). The result is a higher sensitivity and specificity for 
the same prevalence. For example, when 20% of individ-
uals have the disease, the sensitivity and specificity in 
scenario 1 are 85% and 95%, respectively, compared with 
the corresponding values of 98% and 99% in scenario 2. 
Situations like those shown in figure 2 could arise in a 
study in which individuals with and without disease are 
selected from different populations, for example, a 
case-control study with cases identified from hospital 
and controls from the community.
This example also illustrates how the sensitivity is 
affected by the stage and severity of disease or condi-
tion in the population (patient spectrum). The more 
advanced or severe the disease or condition is among 
those individuals affected, the greater the separation in 
the measured variable(s) between people those with 
and without the condition, and the better the test will 
appear to be at discriminating between the two groups. 
For example, a hypothetical pregnancy test would 
appear to perform better if evaluated among a cohort of 
individuals attending an antenatal clinic than if evalu-
ated in the wider community. The antenatal clinic 
cohort would include women who most likely would 
either be definitely pregnant or very likely not to be 
pregnant if they were friends or relatives of the preg-
nant women, whereas the wider community may 
include women in the very early stages of pregnancy. 
importance of the spectrum effect in practice
Although the examples given above are for a situation 
in which the target condition is based on measurement 
of a continuous variable, with the presence or absence 
of the condition based on the value of that variable 
being above or below a threshold, apparent differences 
in test performance arising from variation in preva-
lence and study populations are widespread and can 
be large enough to influence clinical practice. In a 
review of 23 meta-analyses of diagnostic test accuracy, 
statistically significant associations between preva-
lence and sensitivity or specificity were found in one of 
three reviews, with specificity decreasing by between 
0.1% and 0.5% for every 1 percentage point increase in 
prevalence in pooled analysis.10  Many examples also 
illustrate the variation with the affected population’s 
characteristics. For example, Moons and colleagues4 
demonstrated that the performance of an exercise test 
for coronary artery disease varied across patients with 
different characteristics; the positive likelihood ratio 
was 3.8 in individuals with systolic blood pressure 141-
240 mm Hg, and 17.0 in those with systolic blood pres-
sure 100-140 mm Hg.
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Fig 1 | Scenario 1. Variation in (A) positive likelihood ratio (blue solid line) and inverse of negative likelihood ratio (red 
dashed line), and (B) sensitivity (blue solid line) and specificity (red dashed line) with true prevalence of a disease where 
true prevalence of disease is changed by varying the mean of a normal distribution of a continuous variable X while 
keeping the threshold value constant (C and D). True disease is defined as present if X≥7, and absent if X<7. Disease 
prevalence, for illustration, is (C) 2.3%, (D) 49.6%. As prevalence decreases, the positive likelihood ratio (LR+), negative 
likelihood ratio (LR−), and specificity increase, while sensitivity decreases, with 10-fold changes in likelihood ratios and 
variation of 30% in sensitivity and specificity. Values for all plots obtained via simulation as described in the 
supplementary appendix (scenario 1)
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implications for research, clinical practice, and policy
As for prognostic models,11-14 the development and eval-
uation of screening and diagnostic tests should ideally 
be undertaken by use of data from two different cohort 
studies (one for development and one for evaluation), 
which include a wide range of disease states and popu-
lation characteristics. This approach would allow for 
some exploration of the spectrum effect, and ensure 
that the test’s performance is not overestimated by use 
of a sample that is unrepresentative of the wider popu-
lation. If this is not possible and case-control studies 
are used, ideally the study sample should be as similar 
as possible to the population in which the test is 
intended to be used.
In all situations, however, researchers should report 
sufficient data to allow the extent of the potential spec-
trum effect to be assessed. The STARD statement for 
reporting studies of diagnostic accuracy15 recommends 
that authors describe the study participants in detail, 
including the distribution of disease severity. Authors 
should also report estimates of variability of diagnostic 
accuracy between readers, centres, or subgroups of par-
ticipants and estimates of test reproducibility, to allow 
readers to assess any potential spectrum effect. Sub-
group variation in sensitivity and specificity estimates 
can be examined by stratification of the characteristic 
defining the subgroup and by a simple χ2 test of associa-
tion. Subgroup specific receiver operating characteristic 
(ROC) curves can also be constructed and compared, 
while calculating the critical ratio (the difference in 
area under the ROC curves divided by the standard 
deviation of the difference) and comparing it with a 
 normal distribution can provide a quantitative compar-
ison of these ROC curves.16  As Mulherin and Miller 
point out,6  logistic modelling can produce estimates of 
test performance17  among small groups, and facilitates 
investigation of patient characteristics that are multi-
categorical or continuous, enabling the investigator to 
model separately factors that affect sensitivity and 
specificity.4
Care should also be taken by researchers and policy 
makers when comparing the performance of diagnostic 
tests developed in different populations using different 
methods. For example, it is not appropriate to compare 
the sensitivity and specificity of a new diagnostic test 
developed and validated in a secondary care based 
case-control study with the sensitivity and specificity of 
screening programmes in a national population.
Conclusion and implications
When reviewing a study of a new risk prediction, screen-
ing, or diagnostic test and deciding whether to use that 
test in practice, clinicians and policymakers should 
examine the relevance of the study sample to their own 
population. Ideally new tests should be developed and 
evaluated using data from the population(s) in which 
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Fig 2 | Scenario 2. Variation in (A) positive likelihood ratio (blue solid line) and inverse of negative likelihood ratio (red 
dashed line), and (B) sensitivity (blue solid line) and specificity (red dashed line) with true prevalence of a disease where 
true prevalence of disease is changed by altering the distribution of a bimodal distribution of a continuous variable X 
while keeping the threshold value constant (C and D). True disease is defined as present if X≥7, and absent if X<7. Disease 
prevalence, for illustration, is: (C) 17.1%, (D) 41.1%. As prevalence increases, the risk of test misclassification among 
people with the disease decreases and—with this particular underlying distribution of X—results in an increase in 
sensitivity and decrease in the negative likelihood ratio. Values for all plots obtained via simulation as described in the 
supplementary appendix (scenario 2)
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they are intended to be used. If not possible, it is import-
ant to remember that, as a result of the spectrum effect, 
calculations of positive and negative predictive value 
will only partly adjust for differences in disease preva-
lence (box 2). The performance of the test in their own 
population might, therefore, be different from that 
reported in the study, and the potential health gains 
associated with introduction of the test should be inter-
preted with caution.
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Supplementary appendix: Spectrum effect
Box 2: Use of the spectrum effect when considering new diagnostic tests in 
clinical practice: hypothetical example
Dr B, a primary care physician, is considering introducing into his practice a new test 
for bacterial infections in patients with upper respiratory tract symptoms. Dr B finds 
two published reports which have evaluated the test’s performance. In the first 
report, the test was evaluated in a case-control study with 40 patients with bacterial 
infection identified from a hospital ear nose and throat clinic and 60 controls 
attending the orthopaedic clinic in the same hospital. The sensitivity and specificity 
were reported to be 97% and 97%, respectively (fig 2B). Assuming that the prevalence 
of bacterial infection in patients with upper respiratory tract symptoms in primary 
care is about 10%, if Dr B performs the test on a patient and the result is positive, 
there is a 78% probability that the patient has a bacterial infection and that 
antibiotics might be of benefit. 
In the second report, the same test was evaluated in a cross-sectional study in the 
general population in which the prevalence of bacterial infections was 10%. The 
sensitivity and specificity were reported to be 72% and 92%, respectively (fig 1B). 
Using these values instead, if Dr B performs the test on a patient and the result is 
positive, there is only a 50% probability that the patient has a bacterial infection.
